Sareena Shah, Paul Fletcher, Kareem Hamadah, Drake Gilmore, Bryant Staples, Andrea Chadwick, Jianghua He, Jaromme Kim, Brigid Flynn
{"title":"Effect of Preoperative Cannabis Use on Postoperative Pain and Outcomes Following Cardiothoracic Surgery.","authors":"Sareena Shah, Paul Fletcher, Kareem Hamadah, Drake Gilmore, Bryant Staples, Andrea Chadwick, Jianghua He, Jaromme Kim, Brigid Flynn","doi":"10.1177/10892532251374952","DOIUrl":null,"url":null,"abstract":"<p><p>Cannabis use has grown both recreationally and medicinally in the United States over the past decades, alongside increased legalization and social acceptance. However, there remains little research investigating the effects of preoperative cannabis use on postoperative pain in patients undergoing surgery. We conducted a single-center prospective study in adults undergoing cardiac surgery via sternotomy. Patients seen for preoperative consultation in clinic were asked a standardized survey about cannabis use. Clinical data was collected via chart review. Primary outcomes were morphine equivalents in the first 48 hours postoperatively and Visual Analog Scale (VAS) scores. Secondary outcomes were time to extubation, postoperative nausea/vomiting, ICU length of stay (LOS), reoperation, and in-hospital mortality. The non-cannabis user group had 50 patients, and the cannabis user group had 23 patients. Average morphine equivalents in the first 48 hours were similar between cannabis users and non-users (60.98 vs 59.90; <i>P</i> = 0.93), as were VAS scores at 24 hours (5.52 vs 4.84; <i>P</i> = 0.414) and 48 hours (4.74 vs 3.90; <i>P</i> = 0.23). Average time to extubation (minutes) was nearly identical between cannabis users and non-users (718.41 vs 718.67; <i>P</i> = 0.99). There was also no significant difference in average LOS (days) between cannabis users and non-users (2.91 vs 3.48; <i>P</i> = 0.26). There were no differences in postoperative nausea/vomiting, reoperation, or in-hospital mortality. In patients undergoing cardiac surgery via sternotomy, there was no effect of cannabis use on any outcomes, including morphine equivalents, Visual Analog Scale scores, time to extubation, ICU length of stay, postoperative nausea or vomiting, reoperation, or in-hospital mortality.</p>","PeriodicalId":46500,"journal":{"name":"Seminars in Cardiothoracic and Vascular Anesthesia","volume":" ","pages":"10892532251374952"},"PeriodicalIF":1.0000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Cardiothoracic and Vascular Anesthesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/10892532251374952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cannabis use has grown both recreationally and medicinally in the United States over the past decades, alongside increased legalization and social acceptance. However, there remains little research investigating the effects of preoperative cannabis use on postoperative pain in patients undergoing surgery. We conducted a single-center prospective study in adults undergoing cardiac surgery via sternotomy. Patients seen for preoperative consultation in clinic were asked a standardized survey about cannabis use. Clinical data was collected via chart review. Primary outcomes were morphine equivalents in the first 48 hours postoperatively and Visual Analog Scale (VAS) scores. Secondary outcomes were time to extubation, postoperative nausea/vomiting, ICU length of stay (LOS), reoperation, and in-hospital mortality. The non-cannabis user group had 50 patients, and the cannabis user group had 23 patients. Average morphine equivalents in the first 48 hours were similar between cannabis users and non-users (60.98 vs 59.90; P = 0.93), as were VAS scores at 24 hours (5.52 vs 4.84; P = 0.414) and 48 hours (4.74 vs 3.90; P = 0.23). Average time to extubation (minutes) was nearly identical between cannabis users and non-users (718.41 vs 718.67; P = 0.99). There was also no significant difference in average LOS (days) between cannabis users and non-users (2.91 vs 3.48; P = 0.26). There were no differences in postoperative nausea/vomiting, reoperation, or in-hospital mortality. In patients undergoing cardiac surgery via sternotomy, there was no effect of cannabis use on any outcomes, including morphine equivalents, Visual Analog Scale scores, time to extubation, ICU length of stay, postoperative nausea or vomiting, reoperation, or in-hospital mortality.
在过去的几十年里,随着大麻合法化和社会接受度的提高,大麻在美国的娱乐性和药用性都有所增长。然而,很少有研究调查术前使用大麻对手术患者术后疼痛的影响。我们对接受胸骨切开心脏手术的成人进行了一项单中心前瞻性研究。在门诊进行术前咨询的患者被要求进行关于大麻使用的标准化调查。通过图表回顾收集临床资料。主要结果是术后48小时吗啡当量和视觉模拟评分(VAS)评分。次要结局为拔管时间、术后恶心/呕吐、ICU住院时间(LOS)、再手术和院内死亡率。非大麻使用者组有50名患者,大麻使用者组有23名患者。大麻使用者和非使用者在前48小时内的平均吗啡当量相似(60.98 vs 59.90; P = 0.93), 24小时的VAS评分(5.52 vs 4.84; P = 0.414)和48小时(4.74 vs 3.90; P = 0.23)也是如此。大麻使用者和非使用者拔管的平均时间(分钟)几乎相同(718.41 vs 718.67; P = 0.99)。大麻使用者和非使用者之间的平均生存时间(天数)也没有显著差异(2.91 vs 3.48; P = 0.26)。术后恶心/呕吐、再手术或住院死亡率无差异。在通过胸骨切开术接受心脏手术的患者中,大麻的使用对任何结果都没有影响,包括吗啡当量、视觉模拟量表评分、拔管时间、ICU住院时间、术后恶心或呕吐、再手术或住院死亡率。